Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598189 · ClinicalTrials.gov registry record · NA
Ear-Seizure Detection (EarSD) Study
A NA study of Epilepsy and Seizures, sponsored by Felicia Chu.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT06598189: Recruiting NA study of Epilepsy and Seizures, sponsored by Felicia Chu.
NCT06598189 is a NA study of Epilepsy and Seizures that is actively recruiting participants, run by Felicia Chu. The registered enrollment target is 40 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06598189, a NA study of Epilepsy and Seizures, is actively recruiting participants, sponsored by Felicia Chu.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed study is an investigator-initiated study that aims to measure the accuracy of a wearable seizure detection and prediction device (Ear-Seizure Detection Device (EarSD)) by simultaneous recording with conventional video-EEG (Electroencephalogram) on patients with epileptic seizures in the Epilepsy Monitoring Unit of the hospital.
Primary Outcome
Recordings of Bioelectrical signal of subjects with the wearable device and simultaneous continuous EEG data is collected for the duration of hospitalization of participants. Outcome measures reported include number of seizure events per participant.
Interventions
- DEVICE Ear-SD
- DIAGNOSTIC_TEST Electroencephalogram
Study Locations (2)
Massachusetts
- Ummmc-Memorial Campus - Worcester
- Ummmc-University Campus - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-04-03 |
| Est. Completion | 2032-12 |
| Phase | NA |
What NCT06598189 shows while recruiting
NCT06598189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Ear-SD is the first listed.
NCT06598189 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06598189 about?
NCT06598189 is a clinical study titled "Ear-Seizure Detection (EarSD) Study". The proposed study is an investigator-initiated study that aims to measure the accuracy of a wearable seizure detection and prediction device (Ear-Seizure Detection Device (EarSD)) by simultaneous recording with conventional video-EEG (Electroencephalogram) on patients with epileptic seizures in the...
What is the current status of trial NCT06598189?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-04-03. Estimated completion is 2032-12.
What conditions does trial NCT06598189 study?
This clinical trial studies the following conditions: Epilepsy, Seizures.
What interventions are being tested in trial NCT06598189?
The interventions under investigation include: Ear-SD (DEVICE), Electroencephalogram (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06598189?
This trial is sponsored by Felicia Chu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598189 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06598189's enrollment target sits among peer trials
40 92nd of 160 higher than 61 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SeizEAR Safety Study
RECRUITING · NA
-
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
RECRUITING · NA
-
Subcortical Arousal in Perceptual Awareness
RECRUITING · NA
-
Prediction of Anxiety and Memory State
RECRUITING · NA
-
Implementation and Cost Evaluation of Project UPLIFT
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI